Interestingly, treatment with metformin for two months has been shown to reverse the increase in caspase-1 activation and myeloid cell production of IL-1β and IL-18 in drug-naïve T2DM patients by activating AMP-activated protein kinase [66]. This evidence concerns the gene IL18 and type 2 diabetes mellitus.